Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MARCH 2017. Refer to TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | cetuximab (Erbitux®) | ||
| Formulation | 5 mg/ml solution for infusion | ||
| Reference number | 2407 | ||
| Indication | First-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or in combination with FOLFOX |
||
| Company | Merck Serono Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 4315 | ||
| NMG meeting date | 09/09/2015 | ||
| AWMSG meeting date | 09/12/2015 | ||
| Ratification by Welsh Government | 30/12/2015 | ||
| Date of issue | 05/01/2016 | ||
| NICE guidance | TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (external website - opens in new window) |
||
| Commercial arrangement | CAA | ||